Drug resistance is a fundamental factor in treatment failure in diseases like leishmaniasis, although additional factors also play a role in this phenomenon. This volume is the second edition of a well-received book that provides a comprehensive update on the pathology of the disease, as well as on the concept of parasitic drug resistance, its molecular basis, consequences and possible treatments. A valuable resource for scientists both from academia and industry involved in biomedical research and drug design, the book provides the knowledge needed to understand leishmaniasis and to contibute to combatting this disease worldwide.

<p>Prologue

Introduction
Part I Determinant features in Leishmaniasis
Molecular evolution and phylogeny of Leishmania
The role of reservoirs: canine Leishmaniasis
Epidemiology of Leishmaniasis in the time of drug resistance
The role of the immune system in resistance to infection
Part II Challenges in the diagnosis, treatment and control of Leishmaniasis in the times of drug resistance
Co-infection with HIV
Visceral Leishmaniasis
Tegumentary Leishmaniasis
Antimony accounted sequel post Kala-Azar dermal Leishmaniasis
Part III Molecular featrues of drug resistant Leishmania
Genetic Expression and drug resistance, the role of proteomics
The role of AMC transporters in drug-resistant Leishmania
Functional analysis of Leishmania membrane (non AMC) transporters involved in drug resistance
Part IV Pharmacology and chemotherapy of Leishmaniasis
Classical vs. novel treatment regimens
Bioinformatics in Leishmania drug design
Leishmanis mitochondria, a druggable organelle
P-glycoprotein-like transporters in Leishmania: a search for reversal agents
Part V Strategies to circumvent drug resistance in Leishmania
The relevance of susceptibility tests, breakpoints and markers
The concept of fitness in Leishmania.<br></p><p><br></p>